Danshu Capsule and Ursodeoxycholic Acid Capsule in Preventing Recurrence of Choledocholithiasis
Status:
Completed
Trial end date:
2019-07-20
Target enrollment:
Participant gender:
Summary
[objective] to compare the efficacy of Danshu capsule and ursodeoxycholic acid (UDCA) in
preventing recurrence of choledocholithiasis after operation. [methods] one hundred and fifty
ERCP patients with choledocholithiasis were randomly divided into two groups: Danshu group (n
= 75) and UDCA group (n = 75). The Danshu group took 2 Danshu capsules three times a day, and
the UDCA group took 250 mg of Ursofalk twice a day. The clinical efficacy, changes of liver
function indexes before and after treatment and stone recurrence were compared between the
two groups.